Pharmaceutical Policy


CP3 Seminar Series

Is there a place for actuaries in a world typically dominated by researchers, academics, and policy wonks? Join us on September 18 to find out!

340B Debate Perspective

In a perspective piece in the New England Journal of Medicine, CP3 Director Walid Gellad and HPI Director Everette James describe the controversy surrounding the 340B Drug Pricing Program.Read more.

Prescribing habits following overdose

In a recent article in JAMA, researchers compared prescription opioid use and medication-assisted treatment rates before and after an overdose. 

Accelerated Drug Approval

In a recent perspective piece in NEJM, Dr. Gellad discusses the accelerated approval process in the era of expensive drugs. Read more.

Addressing the Opioid Epidemic

In a commentary in JAMA Internal Medicine, Dr. Walid Gellad discusses the opioid epidemic within the Nation's Veteran population. 

Drug Shortages in the US

Each year the United States experiences a shortage of over 100 drugs. In an editorial in JAMA, Drs. Donohue and Angus explore the reasons. 


HPI Highlights

There are no news stories to display.